Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Full results from the SURMOUNT-5 (NCT05822830) phase 3 trial show that tirzepatide (Zepbound) demonstrated superiority compared to semaglutide (Wegovy) across the primary end point and 5 key secondary end points
doi: 10.1016/j.cgh.2012.03.011 55
Patients were randomized 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks
Ultimately, causality cannot be inferred from these observational findings
US$ 22.62
US$ 21.80
US$ 28.41
US$ 20.93
US$ 28.67
US$ 23.94
US$ 28.86
US$ 28.22
US$ 21.66
